CPE
Ms. Jing Wu
PrincipalCPPHARM
Qunrui Li
Deputy General ManagerCR Sanjiu
Vincent Liao
Senior Investment&BD managerCreacion Ventures
Kathy Kang
associateCrinetics Pharmaceuticals
Mr. Greg Solis
Business Strategy AssociateCrossject USA Inc
Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.
Don Zinn
VP US BusinessCrosswave Management
Dr. Charles Hsu
Managing PartnerCRUise
CRUise is the largest SMO Network in MEA region, we are aiming to have a network of clinical research units and Key Opinion Leaders interested in Clinical Research. CRUise will ensure the quality of research by having a network with unified international standards.